Delivery Order SPE2DR25D1053-SPE2DR26FV176
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $40,365.01 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 13, 2025, with an ultimate completion date of November 14, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $25,897.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 19, 2025, with an ultimate completion date of December 22, 2025. This non-competitive award was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement running through December 2026. The contract will be performed at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on October 27, 2025, with completion targeted for October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX). The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,578.79 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) on September 9, 2025, with completion expected by September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $3,835.46 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a $10,892.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an ultimate completion date of November 4, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $18,061.85 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on November 5, 2025, with completion expected by November 6, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,734.27 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by June 3, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $22,423.24 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count bottles) on December 9, 2025, with an ultimate completion date of December 10, 2025. This firm fixed-price, non-set-aside delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026....
- The Defense Logistics Agency awarded a $50,518.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 20, 2025, with an ultimate completion date of June 23, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FV176Delivery Order
The Defense Logistics Agency awarded a $15,139.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on January 2, 2026, with completion scheduled for January 5, 2026. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the broad pharmaceutical supply capabilities that AmerisourceBergen provides through its DLA contract vehicle. As a major pharmaceutical distributor serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems, AmerisourceBergen maintains a comprehensive portfolio spanning specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support military and federal healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.1k | 1/1/26 |